Literature DB >> 18941223

A novel role of CD30L/CD30 signaling by T-T cell interaction in Th1 response against mycobacterial infection.

Ce Tang1, Hisakata Yamada, Kensuke Shibata, Hiromi Muta, Worawidh Wajjwalku, Eckhard R Podack, Yasunobu Yoshikai.   

Abstract

A CD30 ligand (CD30L, CD153) is a type II membrane-associated glycoprotein belonging to the TNF family. To illustrate the potential role of CD30L in CD4(+) Th1 cell responses, we investigated the fate of Ag-specific CD4(+) T cells in CD30L-deficient (CD30L(-/-)) mice after Mycobacterium bovis bacillus Calmette-Guérin (BCG) infection. The number of bacteria was significantly higher in organs of CD30L(-/-) mice than in wild-type (WT) mice 4 wk postinfection. The numbers of purified protein derivative- or Ag85B-specific-IFN-gamma-producing-CD4(+) T cells in spleen, lung, or peritoneal exudate cells were significantly fewer in CD30L(-/-) mice than in WT mice. During the infection, CD30L was expressed mainly by CD44(+)CD3(+)CD4(+) T cells but not by CD3(+)CD8(+) T cells, B cells, dendritic cells, or macrophages. Costimulation with agonistic anti-CD30 mAb or coculturing with CD30L-transfected P815 cells restored IFN-gamma production by CD4(+) T cells from BCG-infected CD30L(-/-) mice. Coculturing with CD30L(+/+)CD4(+) T cells from BCG-infected WT mice also restored the number of IFN-gamma(+)CD30L(-/-)CD4(+) T cells. When transferred into the CD30L(+/+) mice, Ag-specific donor CD30L(-/-) CD4(+) T cells capable of producing IFN-gamma were restored to the compared level seen in CD30L(+/+) CD4(+) T cells on day 10 after BCG infection. When naive CD30L(+/+) T cells were transferred into CD30L(-/-) mice, IFN-gamma-producing-CD4(+) Th1 cells of donor origin were normally generated following BCG infection, and IFN-gamma-producing-CD30L(-/-)CD4(+) Th1 cells of host origin were partly restored. These results suggest that CD30L/CD30 signaling executed by CD30(+) T-CD30L(+) T cell interaction partly play a critical role in augmentation of Th1 response capable of producing IFN-gamma against BCG infection.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18941223     DOI: 10.4049/jimmunol.181.9.6316

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

Review 1.  Brentuximab vedotin.

Authors:  Niels W C J van de Donk; Eugen Dhimolea
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 2.  Searching for "signal 2": costimulation requirements of γδ T cells.

Authors:  Julie C Ribot; Ana debarros; Bruno Silva-Santos
Journal:  Cell Mol Life Sci       Date:  2011-05-04       Impact factor: 9.261

3.  Optimal identification of human conventional and nonconventional (CRTH2-IL7Rα-) ILC2s using additional surface markers.

Authors:  Sucai Liu; Kapil Sirohi; Mukesh Verma; Jerome McKay; Lidia Michalec; Anand Sripada; Tomas Danhorn; Donald Rollins; James Good; Magdalena M Gorska; Richard J Martin; Rafeul Alam
Journal:  J Allergy Clin Immunol       Date:  2020-02-04       Impact factor: 10.793

Review 4.  The TNF Receptor Superfamily in Co-stimulating and Co-inhibitory Responses.

Authors:  Lindsay K Ward-Kavanagh; Wai Wai Lin; John R Šedý; Carl F Ware
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 5.  CD30: from basic research to cancer therapy.

Authors:  Hiromi Muta; Eckhard R Podack
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

6.  CD30 is required for activation of a unique subset of interleukin-17A-producing γδ T cells in innate immunity against Mycobacterium bovis Bacillus Calmette-Guerin infection.

Authors:  Ying Guo; Xun Sun; Kensuke Shibata; Hisakata Yamada; Hiromi Muta; Eckhard R Podack; Yasunobu Yoshikai
Journal:  Infect Immun       Date:  2013-08-05       Impact factor: 3.441

Review 7.  The potential role of thioredoxin 1 and CD30 systems as multiple pathway targets and biomarkers in tumor therapy.

Authors:  Anna Maria Berghella; Patrizia Pellegrini; Tiziana Del Beato; Fabiana Ciccone; Ida Contasta
Journal:  Cancer Immunol Immunother       Date:  2011-07-08       Impact factor: 6.968

8.  Characterization of CD30/CD30L(+) Cells in Peripheral Blood and Synovial Fluid of Patients with Rheumatoid Arthritis.

Authors:  Alessandro Barbieri; Marzia Dolcino; Elisa Tinazzi; Antonella Rigo; Giuseppe Argentino; Giuseppe Patuzzo; Andrea Ottria; Ruggero Beri; Antonio Puccetti; Claudio Lunardi
Journal:  J Immunol Res       Date:  2015-05-19       Impact factor: 4.818

9.  Molecular profiling of tumor-specific TH1 cells activated in vivo.

Authors:  Kristina Berg Lorvik; Ole Audun Werner Haabeth; Trevor Clancy; Bjarne Bogen; Alexandre Corthay
Journal:  Oncoimmunology       Date:  2013-05-01       Impact factor: 8.110

10.  A method for the generation of ectromelia virus (ECTV) recombinants: in vivo analysis of ECTV vCD30 deletion mutants.

Authors:  Ali Alejo; Margarida Saraiva; Maria Begoña Ruiz-Argüello; Abel Viejo-Borbolla; Mar Fernández de Marco; Francisco Javier Salguero; Antonio Alcami
Journal:  PLoS One       Date:  2009-04-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.